ORTHOPEDIATRICS CORP
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
KIDS$33.48-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows -
(Unaudited) (In Thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(13,834) | $(9,692) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 9,807 | 7,928 |
| Stock-based compensation | 5,738 | 5,415 |
| Fair value adjustment of contingent consideration | — | (2,974) |
| Accretion of acquisition installment payable | 537 | 812 |
| Deferred income taxes | (2,955) | (975) |
| Changes in certain operating assets and liabilities: | ||
| Accounts receivable - trade | (4,583) | (8,964) |
| Inventories, net | (10,420) | (11,860) |
| Prepaid expenses and other current assets | (403) | 72 |
| Accounts payable - trade | 4,150 | 9,724 |
| Accrued expenses and other liabilities | 959 | 1,325 |
| Other | (1,778) | (1,645) |
| Net cash used in operating activities | (12,782) | (10,834) |
| INVESTING ACTIVITIES | ||
| Acquisition of Boston O&P, net of cash acquired | (20,693) | — |
| Acquisition of MedTech | — | (3,097) |
| Sale of short-term marketable securities | 49,855 | 72,347 |
| Purchase of short-term marketable securities | — | (44,600) |
| Purchases of property and equipment | (13,144) | (10,563) |
| Net cash provided by investing activities | 16,018 | 14,087 |
| FINANCING ACTIVITIES | ||
| Installment payment for ApiFix | (2,250) | (2,000) |
| Installment payment for MedTech | (1,250) | — |
| Payments on acquisition note | (928) | — |
| Payment of debt issuance costs | (343) | — |
| Payments on mortgage notes | (71) | (71) |
| Net cash used in financing activities | (4,842) | (2,071) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (531) | (335) |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (2,137) | 847 |
| Cash, cash equivalents and restricted cash, beginning of year | $33,027 | $10,462 |
| Cash, cash equivalents and restricted cash, end of period | $30,890 | $11,309 |
| SUPPLEMENTAL DISCLOSURES | ||
| Cash paid for interest | $760 | $11 |
| Transfer of instruments between property and equipment and inventory | $281 | $367 |
| Issuance of common shares for ApiFix installment | $6,929 | $6,178 |
| Issuance of common shares for MedTech installment | $133 | $2,274 |
| Right-of-use assets obtained in exchange for lease liabilities | $— | $293 |
| Debt issuance costs not yet paid | $67 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.